ResMed (RMD) Projected to Post Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is anticipated to post its Q1 2027 results after the market closes on Thursday, October 29th. Analysts expect ResMed to announce earnings of $2.69 per share and revenue of $1.39 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

ResMed (NYSE:RMD) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. The company’s revenue was up 8.6% compared to the same quarter last year. On average, analysts expect ResMed to post $12.11 EPS for the current fiscal year and $13.19 EPS for the next fiscal year.

ResMed Trading Up 0.2%

ResMed stock opened at $253.43 on Tuesday. The company’s fifty day simple moving average is $229.63 and its 200-day simple moving average is $225.54. The company has a quick ratio of 2.42, a current ratio of 3.10 and a debt-to-equity ratio of 0.06. ResMed has a 12 month low of $180.26 and a 12 month high of $277.67. The stock has a market cap of $35.64 billion, a P/E ratio of 22.64, a P/E/G ratio of 1.55 and a beta of 0.75.

ResMed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 24th. Investors of record on Thursday, August 20th were issued a dividend of $0.66 per share. This is a positive change from ResMed’s previous quarterly dividend of $0.60. This represents a $2.64 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Thursday, August 20th. ResMed’s dividend payout ratio is 25.31%.

Insiders Place Their Bets

In other news, CEO Michael Farrell sold 4,991 shares of the stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $226.33, for a total transaction of $1,129,613.03. Following the transaction, the chief executive officer owned 479,803 shares in the company, valued at $108,593,812.99. This represents a 1.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Michael Rider sold 400 shares of the firm’s stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $255.00, for a total transaction of $102,000.00. Following the transaction, the general counsel owned 12,318 shares in the company, valued at $3,141,090. This represents a 3.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,343 shares of company stock valued at $5,396,098 over the last ninety days. Corporate insiders own 0.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RMD. Mizuho set a $240.00 price objective on ResMed in a research report on Tuesday, October 13th. Rothschild & Co Redburn assumed coverage on ResMed in a research report on Wednesday, August 19th. They issued a “neutral” rating and a $230.00 target price on the stock. UBS Group reaffirmed a “buy” rating and issued a $300.00 target price on shares of ResMed in a research report on Tuesday, July 21st. Weiss Ratings raised ResMed from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Piper Sandler reduced their price target on ResMed from $233.00 to $225.00 and set a “neutral” rating for the company in a report on Friday, August 7th. Seven investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $243.23.

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.